Concurrently, dihydrolipoamide branched chain transacylase E2 (DBT) functions as a tumor suppressor by inhibiting tumor progression and rectifying lipid metabolism abnormalities in ccRCC. This evidence concerns the gene DBT and nonpapillary renal cell carcinoma.